Dedicated to every detail that drives CAR T success

Focused on your needs

Developing treatments for patients with cancer and autoimmune disease

Corporate presentations

Clinical-stage programs for hematological and solid tumor indications as well as autoimmune diseases

Transforming treatments for adult Acute Lymphoblastic Leukemia

Our products

1/4

Who we are

Autolus applies extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases and is building a fully integrated, next-generation CAR T company

About us

Our Technology

Chimeric Antigen Receptors

We use Chimeric Antigen Receptors (CARs) to reprogram our T cell product candidates. These receptors combine the tumor recognition domain of an antibody with the activation and costimulatory domains from the T cell receptor to rearm a patient’s T cells to recognize and kill their cancer cells.

Advanced Cell Programming

Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products.

T Cell Manufacturing

We have developed our own proprietary viral vector and semi-automated cell manufacturing processes to engineer a patient's T cells with the CAR and other advanced cell programing modules.

Explore our technology

Abstracts and Publications

See all

New England Journal of Medicine

November 27 2024

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

Nature Medicine

July 06 2023

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Molecular Therapy

March 21 2023